Catherine Passirani

List of Publications by Year
in descending order

63 papers	5,023 citations	94381 37 h-index	123376 61 g-index
63 all docs	63 docs citations	63 times ranked	7349 citing authors

#	Article	IF	Citations
1	Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates, 2022, 60, 100788.	6.5	15
2	Lipid nanocapsules for intracellular delivery of microRNA: A first step towards intervertebral disc degeneration therapy. International Journal of Pharmaceutics, 2022, 624, 121941.	2.6	10
3	p722 ferrocifen loaded lipid nanocapsules improve survival of murine xenografted-melanoma via a potentiation of apoptosis and an activation of CD8+ T lymphocytes. International Journal of Pharmaceutics, 2021, 593, 120111.	2.6	10
4	pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization. Cancers, 2021, 13, 2028.	1.7	11
5	Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors. Cancers, 2021, 13, 2291.	1.7	16
6	Nanomedicine to target multidrug resistant tumors. Drug Resistance Updates, 2020, 52, 100704.	6.5	73
7	Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and in vivo biodistribution improvements. RSC Advances, 2019, 9, 27264-27278.	1.7	11
8	Enhanced and preferential internalization of lipid nanocapsules into human glioblastoma cells: effect of a surface-functionalizing NFL peptide. Nanoscale, 2018, 10, 13485-13501.	2.8	26
9	Nanomedicine as a potent strategy in melanoma tumor microenvironment. Pharmacological Research, 2017, 126, 31-53.	3.1	25
10	Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse. Pharmacological Research, 2017, 126, 54-65.	3.1	37
11	Development and evaluation of injectable nanosized drug delivery systems for apigenin. International Journal of Pharmaceutics, 2017, 532, 757-768.	2.6	25
12	An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors. Scientific Reports, 2016, 6, 21417.	1.6	44
13	Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: Application to Huntington's disease. Biomaterials, 2016, 83, 347-362.	5.7	44
14	Nucleic-Acid Delivery Using Lipid Nanocapsules. Current Pharmaceutical Biotechnology, 2016, 17, 723-727.	0.9	15
15	Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration.. Biotechnology Journal, 2015, 10, 1370-1389.	1.8	33
16	Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules. International Journal of Nanomedicine, 2015, 10, 1259.	3.3	21
17	Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency. Nanomedicine, 2015, 10, 185-191.	1.7	19
18	Polyglutamic acidâ€"PEG nanocapsules as long circulating carriers for the delivery of docetaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 47-54.	2.0	39

#	Article	IF	Citations
19	Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma. Biotechnology Journal, 2014, 9, 1389-1401.	1.8	29
20	Self-assembled biotransesterified cyclodextrins as potential Artemisinin nanocarriers. II: In vitro behavior toward the immune system and in vivo biodistribution assessment of unloaded nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 683-694.	2.0	15
21	FRET Imaging Approaches for <i>in Vitro</i> and <i>in Vivo</i> Characterization of Synthetic Lipid Nanoparticles. Molecular Pharmaceutics, 2014, 11, 3133-3144.	2.3	62
22	Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1667-1677.	1.7	38
23	Surface modification of lipid nanocapsules with polysaccharides: From physicochemical characteristics to in vivo aspects. Acta Biomaterialia, 2013, 9, 6686-6693.	4.1	32
24	A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials, 2013, 34, 6429-6443.	5.7	181
25	The inÂvivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer. Biomaterials, 2013, 34, 6949-6956.	5.7	43
26	EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. International Journal of Pharmaceutics, 2013, 454, 748-755.	2.6	20
27	DNA Nanocarriers for Systemic Administration: Characterization and In Vivo Bioimaging in Healthy Mice. Molecular Therapy - Nucleic Acids, 2013, 2, e64.	2.3	20
28	Photochemical Properties and Activity of Waterâ€Soluble Polymer/C₆₀ Nanohybrids for Photodynamic Therapy. Macromolecular Bioscience, 2013, 13, 106-115.	2.1	4
29	Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 375-387.	1.7	70
30	Active Targeting Strategies for Anticancer Drug Nanocarriers. Current Drug Delivery, 2012, 9, 255-268.	0.8	67
31	Novel metal-based anticancer drugs: a new challenge in drug delivery. Current Opinion in Pharmacology, 2012, 12, 420-426.	1.7	78
32	Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. Journal of Gene Medicine, 2012, 14, 769-775.	1.4	13
33	siRNA LNCs â€“ A novel platform of lipid nanocapsules for systemic siRNA administration. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 448-452.	2.0	30
34	Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 690-693.	2.0	46
35	Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells. Pharmaceutical Research, 2012, 29, 1495-1505.	1.7	95
36	Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. International Journal of Pharmaceutics, 2012, 423, 55-62.	2.6	36

#	Article	IF	Citations
37	Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. International Journal of Pharmaceutics, 2012, 423, 63-68.	2.6	48
38	In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. International Journal of Pharmaceutics, 2012, 423, 108-115.	2.6	28
39	Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative. International Journal of Pharmaceutics, 2012, 426, 231-238.	2.6	29
40	Treatment of 9L Gliosarcoma in Rats by Ferrociphenol-Loaded Lipid Nanocapsules Based on a Passive Targeting Strategy via the EPR Effect. Pharmaceutical Research, 2011, 28, 3189-3198.	1.7	62
41	The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials, 2011, 32, 2106-2116.	5.7	69
42	Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials, 2011, 32, 2327-2333.	5.7	43
43	Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. International Journal of Pharmaceutics, 2011, 403, 201-206.	2.6	85
44	Passive and Active Tumour Targeting with Nanocarriers. Current Drug Discovery Technologies, 2011, 8, 188-196.	0.6	144
45	Brain Tumors: Convection-Enhanced Delivery of Drugs (Method). , 2011, , 207-216.		0
46	Lipid Nanocapsules in Nanomedicine. , 2011, , .		1
47	Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials, 2010, 31, 8393-8401.	5.7	208
48	Local Delivery of Ferrociphenol Lipid Nanocapsules Followed by External Radiotherapy as a Synergistic Treatment Against Intracranial 9L Glioma Xenograft. Pharmaceutical Research, 2010, 27, 56-64.	1.7	54
49	Positively-Charged, Porous, Polysaccharide Nanoparticles Loaded with Anionic Molecules Behave as â€˜Stealthâ€™ Cationic Nanocarriers. Pharmaceutical Research, 2010, 27, 126-133.	1.7	48
50	Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials, 2010, 31, 321-329.	5.7	110
51	Non-viral nanosystems for systemic siRNA delivery. Pharmacological Research, 2010, 62, 100-114.	3.1	100
52	The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine, 2010, 5, 1415-1433.	1.7	147
53	pHâ€Responsive Flowerâ€Type Micelles Formed by a Biotinylated Poly(2â€vinylpyridine)â€<i>block</i>â€poly(ethylene oxide)â€<i>block</i>â€poly(<i>Îµ</i>â€caprolactone) Triblock Copolymer. Advanced Functional Materials, 2009, 19, 1416-1425.	7.8	45
54	Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials, 2009, 30, 2302-2318.	5.7	262

#	Article	IF	Citations
55	The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials, 2009, 30, 3197-3204.	5.7	61
56	Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 2008, 29, 3477-3496.	5.7	737
57	Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. Journal of Controlled Release, 2008, 130, 146-153.	4.8	113
58	Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials, 2006, 27, 108-118.	5.7	178
59	Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27, 4356-4373.	5.7	669
60	Pegylated Nanocapsules Produced by an Organic Solvent-Free Method: Evaluation of their Stealth Properties. Pharmaceutical Research, 2006, 23, 2190-2199.	1.7	67
61	Electrokinetic properties of noncharged lipid nanocapsules: Influence of the dipolar distribution at the interface. Electrophoresis, 2005, 26, 2066-2075.	1.3	77
62	Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Tc	1.7	157
63	Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	2.0	128